United States: The health authorities of the United States have issued a caution regarding a surge in an infrequent bacterial infection that can precipitate meningitis, a grave and frequently fatal ailment wherein an external barrier of the brain or affiliated tissues becomes contaminated and inflamed.
The Centers for Disease Control and Prevention (CDC) conveyed an alert on March 28 concerning the uptick in a specific type of invasive “meningococcal disease” known as serogroup Y.
In the preceding year, there were 422 instances of this ailment reported in the US — the highest tally in a single year since 2014. Thus far this year, there have been 143 reported instances. This implies that infections are poised to surpass the figures from 2023, according to the CDC.
The majority of cases last year did not involve meningitis, although a minimum of 17 fatalities were recorded. The incidents were more prevalent among adults aged 30 to 60, individuals of Black ethnicity, and those afflicted with HIV, as per the CDC’s announcement.
HIV is a viral infection that can lead to AIDS, a severe condition that can compromise the body’s innate defense mechanisms.
The infection induced by meningococcal ailment can result in manifestations such as elevated body temperature, cephalic and upper body discomfort, queasiness, and emesis.
The bacteria can also instigate an infection in the bloodstream, leading to symptoms such as chilliness, lethargy, frigid extremities, rapid respiration, dyspepsia, or skin discoloration.
The infection can be managed with pharmaceuticals like antibiotics. However, prompt intervention is imperative for favorable outcomes. An estimated 10 to 15 percent of afflicted individuals perish, and survivors may suffer auditory impairment or necessitate surgical amputation of body parts.
Furthermore, vaccinations against meningococcal ailment are available.
Authorities recommend that all juveniles receive a “meningococcal conjugate vaccine” around the age of 11. Since vaccine efficacy wanes over time, the CDC also advises a booster dose at age 16.
Moreover, the CDC advocates for immunization among individuals at heightened risk, such as those residing in regions experiencing outbreaks or those afflicted with HIV or other underlying medical conditions.